News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Raptor Pharmaceutical Inc. (RPTP) Obtains Tissue Fibrotic Disease Intellectual Property Related to Cysteamine


10/10/2012 9:53:23 AM

NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the Company has acquired exclusive world-wide rights to intellectual property related to cysteamine and related compounds in the potential treatment of tissue fibrosis from the Seattle Children's Research Institute ("SCRI").

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES